title: Identification of multiple novel protein biomarkers shed by human serous ovarian tumors into the blood of immunocompromised mice and verified in patient sera.
abstract: The most cancer-specific biomarkers in blood are likely to be proteins shed directly by the tumor rather than less specific inflammatory or other host responses. The use of xenograft mouse models together with in-depth proteome analysis for identification of human proteins in the mouse blood is an under-utilized strategy that can clearly identify proteins shed by the tumor. In the current study, 268 human proteins shed into mouse blood from human OVCAR-3 serous tumors were identified based upon human vs. mouse species differences using a four-dimensional plasma proteome fractionation strategy. A multi-step prioritization and verification strategy was subsequently developed to efficiently select some of the most promising biomarkers from this large number of candidates. A key step was parallel analysis of human proteins detected in the tumor supernatant, because substantially greater sequence coverage for many of the human proteins initially detected in the xenograft mouse plasma confirmed assignments as tumor-derived human proteins. Verification of candidate biomarkers in patient sera was facilitated by in-depth, label-free quantitative comparisons of serum pools from patients with ovarian cancer and benign ovarian tumors. The only proteins that advanced to multiple reaction monitoring (MRM) assay development were those that exhibited increases in ovarian cancer patients compared with benign tumor controls. MRM assays were facilely developed for all 11 novel biomarker candidates selected by this process and analysis of larger pools of patient sera suggested that all 11 proteins are promising candidate biomarkers that should be further evaluated on individual patient blood samples.
authors.affiliation: Center for Systems and Computational Biology, and Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, Pennsylvania, United States of America.
authors.forename: Lynn A
authors.initials: LA
authors.lastname: Beer
authors.forename: Huan
authors.initials: H
authors.lastname: Wang
authors.forename: Hsin-Yao
authors.initials: HY
authors.lastname: Tang
authors.forename: Zhijun
authors.initials: Z
authors.lastname: Cao
authors.forename: Tony
authors.initials: T
authors.lastname: Chang-Wong
authors.forename: Janos L
authors.initials: JL
authors.lastname: Tanyi
authors.forename: Rugang
authors.initials: R
authors.lastname: Zhang
authors.forename: Qin
authors.initials: Q
authors.lastname: Liu
authors.forename: David W
authors.initials: DW
authors.lastname: Speicher
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D014408:Biomarkers, Tumor / Q000097:blood*; D045744:Cell Line, Tumor; D002853:Chromatography, Liquid; D004195:Disease Models, Animal; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D016867:Immunocompromised Host; D013058:Mass Spectrometry; D051379:Mice; D008969:Molecular Sequence Data; D008970:Molecular Weight; D009363:Neoplasm Proteins / Q000097:blood* / Q000737:chemistry; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000097:blood* / Q000235:genetics; D010051:Ovarian Neoplasms / Q000097:blood* / Q000235:genetics; D020543:Proteome / Q000737:chemistry / Q000378:metabolism; D015203:Reproducibility of Results; D013194:Staining and Labeling; D023041:Xenograft Model Antitumor Assays
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D020543:Proteome
references.citation: Cancer Prev Res (Phila). 2011 Mar;4(3):365-74
references.pmid: 21372036
references.citation: Clin Cancer Res. 2004 Mar 1;10(5):1796-806
references.pmid: 15014034
references.citation: Hum Reprod. 1989 Jan;4(1):1-12
references.pmid: 2651469
references.citation: Genome Biol. 2009;10(11):R130
references.pmid: 19919682
references.citation: Cancer Res. 2003 Jul 1;63(13):3695-700
references.pmid: 12839961
references.citation: Clin Cancer Res. 2003 Dec 15;9(17):6316-25
references.pmid: 14695130
references.citation: Proteomics. 2004 Apr;4(4):1175-86
references.pmid: 15048997
references.citation: Mol Cell Proteomics. 2009 Apr;8(4):661-9
references.pmid: 19047685
references.citation: Cancer Res. 2009 Feb 1;69(3):728-30
references.pmid: 19155298
references.citation: Mol Cancer Ther. 2008 Jan;7(1):27-37
references.pmid: 18187805
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51
references.pmid: 8411259
references.citation: J Pathol. 2007 Sep;213(1):46-55
references.pmid: 17668415
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Apr 15;849(1-2):43-52
references.pmid: 17140865
references.citation: Proc Natl Acad Sci U S A. 2001 Jan 30;98(3):1176-81
references.pmid: 11158614
references.citation: J Ovarian Res. 2010 Sep 10;3:21
references.pmid: 20831812
references.citation: Proteomics. 2012 Jun;12(11):1883-91
references.pmid: 22623176
references.citation: Proteomics. 2005 Aug;5(13):3329-42
references.pmid: 16052622
references.citation: Electrophoresis. 2001 May;22(9):1603-15
references.pmid: 11425216
references.citation: J Proteome Res. 2011 Mar 4;10(3):1126-38
references.pmid: 21142075
references.citation: N Engl J Med. 2009 Jul 9;361(2):170-7
references.pmid: 19587342
references.citation: Expert Rev Proteomics. 2005 Jun;2(3):295-306
references.pmid: 16000077
references.citation: Cancer Res. 2001 Oct 15;61(20):7388-93
references.pmid: 11606367
references.citation: J Physiol. 2005 Feb 15;563(Pt 1):23-60
references.pmid: 15611012
references.citation: PLoS One. 2010 Jun 15;5(6):e11137
references.pmid: 20559444
references.citation: J Proteome Res. 2008 Jan;7(1):339-51
references.pmid: 18076136
references.citation: Mol Cell Proteomics. 2007 Aug;6(8):1299-317
references.pmid: 17494944
references.citation: PLoS One. 2009 Nov 19;4(11):e7916
references.pmid: 19936259
references.citation: N Engl J Med. 1983 Oct 13;309(15):883-7
references.pmid: 6310399
references.citation: Mol Cell Proteomics. 2006 Apr;5(4):573-88
references.pmid: 16332733
references.citation: Biomark Insights. 2007 Feb 07;1:1-48
references.pmid: 19690635
references.citation: Cancer Prev Res (Phila). 2011 Mar;4(3):375-83
references.pmid: 21372037
references.citation: PLoS One. 2008 Jun 18;3(6):e2425
references.pmid: 18560578
references.citation: Bioinformatics. 2010 Apr 1;26(7):966-8
references.pmid: 20147306
references.citation: Biomark Med. 2009 Jun 1;3(3):275-288
references.pmid: 19684876
references.citation: Ai Zheng. 2004 Feb;23(2):141-5
references.pmid: 14960231
references.citation: N Engl J Med. 2004 Dec 9;351(24):2519-29
references.pmid: 15590954
references.citation: Gynecol Oncol. 2011 Feb;120(2):233-8
references.pmid: 21075439
references.citation: J Proteome Res. 2012 Feb 3;11(2):678-91
references.pmid: 22032327
references.citation: J Proteome Res. 2011 Nov 4;10(11):4993-5005
references.pmid: 21955121